NCT05039866Active, not recruitingPhase 2
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Observational
- Enrollment
- 32 (actual)
- First submitted
- 20 Aug 2021
- Start date
- Aug 2021
- Primary completion date
- Mar 2029
- Lead sponsor
- Sangamo Therapeutics
- Diseases
- Fabry disease
- NCT number
- NCT05039866
- EU CT number
- 2024-512700-18-00
What you commit to
- Study type: Observational · Phase 2
- Participants enrolled: 32
- From Aug 2021 to the primary completion date, Mar 2029
- 13 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -This study has no exclusion criteria
Who the study is looking for
- Subjects who received ST-920 therapy in a separate parent trial
- Subjects who have consented to participate in this LTFU study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Melbourne Hospital Coordinator of this site? Confirm its status | Parkville | Australia | Unknown status |
| M.A.G.I.C. Clinic Ltd. Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| Universitaetsklinikum Wuerzburg AöR Coordinator of this site? Confirm its status | Wuerzburg | Germany | Active, not recruiting |
| Addenbrooke's Hospital Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Unknown status |
| Royal Free Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Emory University School of Medicine Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) Coordinator of this site? Confirm its status | Fairfax | United States | Unknown status |
| University of Iowa Hospital and Clinics Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
| University of California, Irvine Coordinator of this site? Confirm its status | Irvine | United States | Unknown status |
| University of Minnesota Medical Center Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Mt Sinai Hospital Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| University of South Florida Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.